We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

Back to rankings

0 hedge funds and large institutions have $0 invested in Strongbridge Biopharma plc. in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 49 → 0 (-49)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $69.8M → $0 (-$69.8M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 49

Holders
–
Holders Change
-49
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
49
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

1
CC
Caxton Corporation
New Jersey
-$16.4M
2
SCM
Stonepine Capital Management
Oregon
-$9.16M
3
NMC
NEA Management Company
Maryland
-$8.45M
4
RCMNY
Rubric Capital Management (New York)
New York
-$6.27M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$4.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
1
Caxton Corporation
New Jersey
– -$16.4M -8,024,542 Closed
SCM
2
Stonepine Capital Management
Oregon
– -$9.16M -4,489,687 Closed
NMC
3
NEA Management Company
Maryland
– -$8.45M -4,141,308 Closed
RCMNY
4
Rubric Capital Management (New York)
New York
– -$6.27M -3,072,732 Closed
Vanguard Group
5
Vanguard Group
Pennsylvania
– -$4.49M -2,200,172 Closed
Man Group
6
Man Group
United Kingdom
– -$4.01M -1,966,636 Closed
Morgan Stanley
7
Morgan Stanley
New York
– -$3.62M -1,774,307 Closed
Tudor Investment Corp
8
Tudor Investment Corp
Connecticut
– -$3.12M -1,529,426 Closed
Renaissance Technologies
9
Renaissance Technologies
New York
– -$2.8M -1,371,400 Closed
O
10
OrbiMed
New York
– -$1.62M -794,675 Closed
Millennium Management
11
Millennium Management
New York
– -$1.19M -583,163 Closed
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
– -$1.18M -576,979 Closed
WAM
13
Weiss Asset Management
Massachusetts
– -$1.01M -494,093 Closed
Geode Capital Management
14
Geode Capital Management
Massachusetts
– -$952K -466,863 Closed
YCM
15
Yakira Capital Management
Connecticut
– -$696K -341,303 Closed
OAC
16
OMERS Administration Corp
Ontario, Canada
– -$429K -210,401 Closed
BlackRock
17
BlackRock
New York
– -$412K -201,840 Closed
DT
18
Diversified Trust
Tennessee
– -$405K -198,534 Closed
Goldman Sachs
19
Goldman Sachs
New York
– -$400K -196,365 Closed
FFH
20
Fairfax Financial Holdings
Ontario, Canada
– -$392K -193,107 Closed
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
– -$317K -155,457 Closed
E
22
Ergoteles
New York
– -$313K -153,518 Closed
Two Sigma Advisers
23
Two Sigma Advisers
New York
– -$307K -150,600 Closed
State Street
24
State Street
Massachusetts
– -$281K -137,728 Closed
Jane Street
25
Jane Street
New York
– -$247K -121,202 Closed
1
2

SBBP Hedge Fund Activity: Q4 2021 in Review

0 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2021, worth a combined $0 — down 100% from $69.8M a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of SBBP and 0 opened new positions — a net loss of 49 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Caxton Corporation, exiting entirely with an estimated $16.4M sold.

  • 0 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2021, down from 49 in Q3 2021.
  • Funds reported $0 of Strongbridge Biopharma plc. stock for Q4 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Strongbridge Biopharma plc. positions in Q4 2021 and 49 closed out, a net change of -49 holders.
  • The largest Strongbridge Biopharma plc. seller in Q4 2021 was Caxton Corporation, an estimated $16.4M sold.

Based on aggregated 13F filings for Q4 2021.